

PCT
7 FEB 2002
PATENT

#13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Burchardt, et al.

Group No.:

Serial No.: 09/830,741

Examiner:

Filed: 04/30/2001

For: Phosphinate Peptide Analogs for the Treatment of Fibrotic Disorders

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The supplemental information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT


Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 31,108


Telephone: (203) 812-2712

Date: 13 Feb. '02



William F. Gray
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

CERTIFICATE OF MAILING FOR PCT APPLICATION NO. 01/19518
The undersigned hereby certifies that this paper and any papers referred to as attached, is/are being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on this 14th day of FEB. 2002



Signature of Person Certifying